Can a targeted pill slow brain tumor growth after surgery?
NCT ID NCT05592743
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
This expanded access program offers vorasidenib, an oral drug, to people aged 12 and older with IDH-mutated glioma who have had surgery. The drug targets specific genetic mutations in tumor cells. The goal is to see if it can help control the disease without immediate need for radiation or chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vorasidenib, an oral drug that targets IDH mutations in glioma cells
- What this could lead to
- If it works, vorasidenib could offer a way to delay or avoid chemotherapy and radiation for people with certain brain tumors.
- What could go wrong
- This is an expanded access program, not a controlled trial, so results may be less clear. Side effects are possible, and the drug may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tiny implant trap brain tumor cells and make radiation work better?
- Brain surgery gets a GPS: network maps may help remove tumors while preserving function
- Liver tumors targeted directly: old pump, new drug
- Time-Restricted eating may ease lingering cancer fatigue
- Brain electrode recordings during awake surgery could sharpen tumor removal
- AI reads brain scans to spot tumors without a biopsy